Keywords: Molecular Imaging, Multimodal We developed a novel nanoplatform-based MMP9-responsive T2–T1 switching MRI contrast agent, which can be used not only for non-invasive visualization and quantitative analysis of MMP9 activity, but also as a carrier in photothermal sensitization chemotherapy. The nanoplatform acts as a T2 contrast agent in physiological conditions ,then transform into a T1 contrast agent by MMP9 stimulus. We have demonstrated that the changes R1 and R2/R1 values are MMP9 concentration dependent in tumors. The combination of PMPSD with laser irradiation was more effective than single chemo-/photothermal therapy, and up-regulation of MMP9 in the tumor could eanhance the nanoplatform’s therapeutic effect.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords